APTIM Receives City & State NY’s Responsible 100 Award for 2020

New York, Dec. 18, 2020 (GLOBE NEWSWIRE) — We are proud of the incredible work the APTIM team in New York has accomplished in 2020 and thank City & State for honoring APTIM CEO Mark Fallon with this year’s Responsible 100 award. This award honors New York’s 100 most outstanding corporate citizens.

In an extraordinary year, how we define both resiliency and strength has changed. Resiliency is not just structural, but also personal. In our decades of leading disaster recovery, mitigation, transportation, resiliency and sustainability work, we prioritize social infrastructure, with an empowered workforce, first.

APTIM has been proudly supporting the communities in New York with projects including NYCHA’s Hurricane Sandy Resiliency and Recovery Program, New York City’s Department of Design and Construction Water Management, and the Port Authority of New York and New Jersey Design Management for the JFK International Airport Redevelopment Program. 

Mark Fallon became CEO in April of 2020, during one of the worst public health crises in our country’s history. Under his leadership, disaster response dedicated staff worked with the US Army Corp of Engineers and FEMA rapidly deploying on the ground expertise and logistical support to aid in our country’s pandemic response and recovery.



Brian Sacco
APTIM
833-862-7846
[email protected]

LOOMING DEADLINE: Zhang Investor Law Reminds Investors with Losses of the Deadline in Securities Class Action Lawsuit Against Intercept Pharmaceuticals, Inc. – ICPT

NEW YORK, Dec. 18, 2020 (GLOBE NEWSWIRE) — Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) between September 28, 2019 and October 7, 2020, inclusive (the “Class Period”).

To join the class action, go to http://zhanginvestorlaw.com/join-action-form/?slug=intercept-pharmaceuticals-inc&id=2505 or call Sophie Zhang, Esq. toll-free at 800-991-3756 or email [email protected] for information on the class action.

如果您想加入这个集体诉讼案,请在这里提交您的信息。http://zhanginvestorlaw.com/join-action-form/?slug=intercept-pharmaceuticals-inc&id=2505

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: defendants downplayed the true scope and severity of safety concerns associated with Ocaliva’s (obeticholic acid (“OCA”)) use in treating primary biliary cholangitis; the foregoing increased the likelihood of an FDA investigation into Ocaliva’s development, thereby jeopardizing Ocaliva’s continued marketability and the sustainability of its sales; any purported benefits associated with OCA’s efficacy in treating nonalcoholic steatohepatitis (“NASH”) were outweighed by the risks of its use; as a result, the FDA was unlikely to approve Intercept’s New Drug Application for OCA in treating patients with liver fibrosis due to NASH; and as a result of the foregoing, defendants’ positive statements about Intercept’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

If you wish to serve as lead plaintiff, you must move the Court no later than January 4, 2021.

Lead plaintiff status is not required to seek compensation.  You may retain counsel of your choice.  You may remain an absent class member and take no action at this time.

Zhang Investor Law represents investors worldwide. Attorney Advertising. Prior results do not guarantee similar outcomes.

Zhang Investor Law P.C.
99 Wall Street, Suite 232
New York, New York 10005
[email protected]
tel: (800) 991-3756



Oregon Bancorp Increases Quarterly Dividend

Oregon Bancorp Increases Quarterly Dividend

SALEM, Ore.–(BUSINESS WIRE)–
The Board of Directors of Oregon Bancorp, Inc. (OTCBB: ORBN), parent company of Willamette Valley Bank, declared a quarterly dividend of $0.26 per share. This represents an increase of $0.15 per share, or 136%, over the prior quarterly dividend amount. The dividend is payable on January 15, 2021 to shareholders of record as of December 31, 2020.

About Oregon Bancorp, Inc.

Oregon Bancorp, Inc. is the parent company of Willamette Valley Bank (Bank), a community bank headquartered in Salem, Oregon. The Bank operates full-service branches in Salem, Keizer, Silverton, and Albany, Oregon. The Bank also operates Home Loan Centers in Bend, Eugene, Grants Pass, Medford, Tualatin, Portland and West Linn, Oregon, Vancouver, Yakima, Spokane and Newport, Washington, and Coeur d’Alene and Meridian, Idaho. For more information about Oregon Bancorp, Inc. or its subsidiary, Willamette Valley Bank, please call (503)485-2222 or visit our website at www.willamettevalleybank.com.

Ryan Dempster

Oregon Bancorp, Inc.

503-485-2222

[email protected]

KEYWORDS: Oregon United States North America

INDUSTRY KEYWORDS: Banking Professional Services Finance

MEDIA:

Logo
Logo

HRO Today Names ISG Advisors Among the 2020 Superstars Leading Workforces Through the Pandemic

Debora Card, Stacey Cadigan and Julie Fernandez recognized as top HRO experts

STAMFORD, Conn., Dec. 18, 2020 (GLOBE NEWSWIRE) — HR experts are fearlessly leading their organizations through the uncertain world of pandemic disruption, the editors of HRO Today magazine said in recognizing leaders from Information Services Group (ISG) (Nasdaq: III), a leading global technology research and advisory firm, among the publication’s 2020 Superstars.

Debora Card, partner, was honored for the seventh consecutive year; Stacey Cadigan, partner, was named for the fifth consecutive year, and Julie Fernandez, partner and leader of the firm’s HR Technology and Services practice, was included for the fourth consecutive year. ISG was again the most recognized advisory firm in the 2020 voting, with three of the 17 consultants, advisors, analysts, academics, investors and thought leaders cited by the magazine.

“Julie, Stacey and Deb have put in another impactful year of effort on behalf of our clients, and we could not be prouder of their well-deserved recognition by HRO Today,” said Todd Lavieri, vice chairman and president, ISG Americas and Asia Pacific. “In a year when the economy and business climate were dramatically altered by the pandemic, these advisors worked closely and quickly with our clients to fundamentally transform their technology and their organizations for the better.”

“In this climate, HR leaders have taken center stage, leading their workforces through the pandemic with an eye for employee well-being, connectivity, and agility,” the editors of HRO Today said in announcing the awards. “This year has presented challenges for employers and employees alike, but the HR leaders listed within these pages have tackled each obstacle to emerge even stronger and more innovative than before.”

ISG HR Technology and Delivery Services is a leading independent advisor on all aspects of HR transformation, working closely with clients as they create a business case for technology investment, select the best platform for their needs and manage organizational and process change.

Card has 30 years’ experience in shared services, outsourcing and HR management to help clients define and implement their HR technology and service delivery strategies. Cadigan is a key contributor in all aspects of HR advisory, with particular expertise in recruitment process outsourcing, HR technology and talent management. Fernandez’s expertise ranges from HR technology, HR automation and RPA, shared services, HR providers and global payroll.

Awards are given in three categories: Providers; Practitioners; and Consultants, Advisors, Analysts, Academics, Investors and Thought Leaders. Superstars were nominated externally and by the HRO Today staff. To see the list of honorees in the third category, visit this webpage. A complete list of all winners is available here.

About HRO Today and HRO Today Global

HRO Today and HRO Today Global are the properties of SharedXpertise Media and offer the broadest and deepest reach into the HR industry. Their magazines, web portals, research, e-newsletters, events and social networks reach over 180,000 senior-level HR decision-makers with rich, objective, game-changing content.

About ISG

ISG (Information Services Group) (Nasdaq: III) is a leading global technology research and advisory firm. A trusted business partner to more than 700 clients, including more than 75 of the world’s top 100 enterprises, ISG is committed to helping corporations, public sector organizations, and service and technology providers achieve operational excellence and faster growth. The firm specializes in digital transformation services, including automation, cloud and data analytics; sourcing advisory; managed governance and risk services; network carrier services; strategy and operations design; change management; market intelligence and technology research and analysis. Founded in 2006, and based in Stamford, Conn., ISG employs more than 1,300 digital-ready professionals operating in more than 20 countries—a global team known for its innovative thinking, market influence, deep industry and technology expertise, and world-class research and analytical capabilities based on the industry’s most comprehensive marketplace data. For more information, visit www.isg-one.com.

# # #



Will Thoretz
Information Services Group, Inc. 
+1 203 517 3119
[email protected]

Jim Baptiste
Matter Communications for ISG
+1 978 518 4527
[email protected]

Under Armour Completes Sale Of The MyFitnessPal Platform To Francisco Partners

PR Newswire

BALTIMORE, Dec. 18, 2020 /PRNewswire/ — Under Armour, Inc. (NYSE: UA, UAA), a global leader in branded athletic performance apparel, footwear and accessories, today announced that it has completed the sale of the MyFitnessPal platform to Francisco Partners.

This announcement follows the October 30, 2020 news release in which Under Armour detailed that it had entered into a definitive agreement with Francisco Partners regarding the sale of this business for a transaction value of $345 million, inclusive of the achievement of potential earn-out payments. Debt financing for the transaction was provided by MidCap Financial.

About Under Armour, Inc.

Under Armour, Inc., headquartered in Baltimore, Maryland, is a leading inventor, marketer and distributor of branded athletic performance apparel, footwear and accessories. Designed to empower human performance, Under Armour’s innovative products and experiences are engineered to make athletes better. For further information, please visit http://about.underarmour.com.

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/under-armour-completes-sale-of-the-myfitnesspal-platform-to-francisco-partners-301196114.html

SOURCE Under Armour, Inc.

Athabasca Minerals Inc. Virtually Opens The Market

Canada NewsWire

TORONTO, Dec. 18, 2020 /CNW/ – Robert Beekhuizen, Chief Executive Officer, Athabasca Minerals Inc. (TSXV: AMI) and his team joined Berk Sumen, Head, Company Services, TMX Group to celebrate the joint venture Duvernay Sand Project and open the market.

Duvernay Sand Project is one of the greenest projects of its kind, and one that will help reduce the reliance on imported sand with a local solution that brings sustainability and economic benefits to Canada.

Athabasca Minerals Inc. is an integrated group of companies focused on industrial minerals and technology, including exploration and development, aggregates marketing and midstream supply-logistics solutions. Business activities include aggregate production, sales and royalties from corporate-owned pits, management services of third-party pits, acquisitions of sand and gravel operations, integrated supply/delivery solutions of industrial minerals, and new venture development. The Corporation is strategically focused on growing its four business units: AMI Aggregates, AMI RockChain, AMI Silica and TerraShift Engineering. Management is continually pursuing opportunities for sustained growth and diversification in supplying aggregate products and industrial minerals. https://www.athabascaminerals.com/ 


For Market Openings:

 Media may pick up a feed from the TOC (television operations centre) for all market open ceremonies. The feed is named TSX Transmit 1 (SD-SDI) and is produced at the TMX Broadcast Centre and sent live to the TOC. To pick up the feed via the Dejero network, please contact [email protected]. The client feature video will begin playing on the TMX media wall at approximately 9:27 a.m. ET and the markets will open with the sound of a siren at 9:30 a.m. ET.


Date:   Friday, December 18, 2020
Time:   9:00am – 9:30am
Place:  Virtually Broadcast

SOURCE TMX Group Limited

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against JPMorgan Chase & Co. (JPM)

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against JPMorgan Chase & Co. (JPM)

LOS ANGELES–(BUSINESS WIRE)–The Law Offices of Frank R. Cruz reminds investors of the upcoming December 23, 2020 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased JP Morgan Chase & Co. (“JPMorgan” or the “Company”) (NYSE: JPM) securities between February 23, 2016 and September 23, 2020, inclusive (the “Class Period”).

If you are a shareholder who suffered a loss, click here to participate.

On November 6, 2018, the U.S. Department of Justice (“DOJ”) announced in a press release that former JPMorgan precious metals trader John Edmonds had pled guilty to commodities fraud and spoofing conspiracy—i.e., placing larger orders with no intention of executing, thereby creating an artificial impression of high demand or supply of the commodity in question.

On August 20, 2019, the DOJ then announced that another JPMorgan employee, Christian Trunz, pled guilty to spoofing charges, admitting that he had learned to spoof from more senior traders and had engaged in spoofing with the knowledge and consent of his supervisors.

On September 23, 2020, Bloomberg reported that the Company was nearing a settlement to resolve the spoofing charges, stating that JPMorgan was “poised to pay close to $1 billion.”

On this news, JPMorgan’s stock price fell $2.04 per share, or 2.15%, to close at $92.74 per share on September 23, 2020.

On September 29, 2020, the Commodity Futures Trading Commission formally announced that it had ordered JPMorgan to pay $920 million to settle spoofing and market manipulation charges.

The complaint filed alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) traders at the Company, with the knowledge and consent of their superiors, manipulated the precious metals market by “spoofing,” or placing fake orders to generate the appearance of market demand; (2) the Company had insufficient controls and compliance protocols to enable it to identify and stop the misconduct; (3) the Company’s earnings in the physical commodity market were, at least in part, ill-gotten; (4) such conduct would result in enhanced regulatory scrutiny; (5) the Company provided misleading information to CFTC investigators at early stages of the investigation into the misconduct; (6) resolution of the governmental investigation into the Company would result in a record-breaking $920 million fine; and (7) as a result, Defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Follow us for updates on Twitter: twitter.com/FRC_LAW.

If you purchased or otherwise acquired JPMorgan securities during the Class Period, you may move the Court no later than December 23, 2020 to request appointment as lead plaintiff in this putative class action lawsuit. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 1999 Avenue of the Stars, Suite 1100, Los Angeles, California 90067 at 310-914-5007, by email to [email protected], or visit our website at www.frankcruzlaw.com. If you inquire by email please include your mailing address, telephone number, and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

The Law Offices of Frank R. Cruz, Los Angeles

Frank R. Cruz, 310-914-5007

[email protected]

www.frankcruzlaw.com

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Legal Professional Services

MEDIA:

Logo
Logo

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Innate Pharma SA (IPHA)

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Innate Pharma SA (IPHA)

LOS ANGELES–(BUSINESS WIRE)–The Law Offices of Frank R. Cruz reminds investors of the upcoming December 22, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Innate Pharma SA (“Innate” or the “Company”) (NASDAQ: IPHA) securities between March 10, 2020 and September 8, 2020, inclusive (the “Class Period”).

If you are a shareholder who suffered a loss, click here to participate.

On October 23, 2018, Innate and AstraZeneca plc (“AstraZeneca”) announced an expansion of a pre-existing collaboration agreement, whereby AstraZeneca acquired 9.8% equity stake in Innate and obtained full oncology rights to monalizumab, a first-in-class humanized anti-NKG2A antibody. As part of this agreement, Innate would receive $100 million in milestone payments at the start of the first Phase 3 clinical trial for monalizumab.

On September 8, 2020, Innate announced that it had amended its collaboration agreement with AstraZeneca. Innate “will now receive a $50 million payment upon AstraZeneca’s dosing of the first patient in the Phase 3 trial, and a $50 million payment after the interim analysis demonstrates the combination meets a pre-defined threshold of clinical activity.”

On this news, the Company’s American Depositary Share (“ADS”) price fell $1.62 per share, or 26.6%, to close at $4.45 per ADS on September 8, 2020.

The complaint filed alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Innate touted the results of their various Phase 2 trials as being within expectations; (2) Innate continued to reassure investors that they were eligible for the $100 million payment upon first dosing of Phase 3 trials; (3) Innate failed to timely disclose their renegotiations with AstraZeneca to split the $100 million payment into two $50 million payments, to be partially contingent on performance during the Phase 3 trials; and (4) as a result, Defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Follow us for updates on Twitter: twitter.com/FRC_LAW.

If you purchased or otherwise acquired Innate securities during the Class Period, you may move the Court no later than December 22, 2020 to request appointment as lead plaintiff in this putative class action lawsuit. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 1999 Avenue of the Stars, Suite 1100, Los Angeles, California 90067 at 310-914-5007, by email to [email protected], or visit our website at www.frankcruzlaw.com. If you inquire by email please include your mailing address, telephone number, and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

The Law Offices of Frank R. Cruz, Los Angeles

Frank R. Cruz, 310-914-5007

[email protected]

www.frankcruzlaw.com

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Legal Professional Services

MEDIA:

Logo
Logo

DEADLINE ALERT for SPLK and BSX: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

LOS ANGELES, Dec. 18, 2020 (GLOBE NEWSWIRE) — The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion.

Investors suffering losses on their investments are encouraged to contact The Law Offices of Frank R. Cruz to discuss their legal rights in these class actions at 310-914-5007 or by email to [email protected].

Splunk Inc. (NASDAQ: SPLK)
Class Period:   October 21, 2020 – December 2, 2020
Lead Plaintiff Deadline: February 2, 2021

The complaint filed alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Splunk was not closing deals with its largest customers in the third fiscal quarter of 2021; (2) Splunk was not hitting the financial targets it had previously announced; and (3) as a result, Defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Boston Scientific Corporation (NYSE: BSX)
Class Period: April 24, 2019 – November 16, 2020
Lead Plaintiff Deadline:   February 2, 2021

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) the LOTUS Edge Aortic Valve System’s product delivery system was dysfunctional and threatened the continued viability of the entire product line; (2) as a result, the Company had materially overstated the continued commercial viability and profitability of the LOTUS Edge Aortic Valve System; and (3) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

Follow us for updates on Twitter: twitter.com/FRC_LAW.

To be a member of these class actions, you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about these class actions, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 1999 Avenue of the Stars, Suite 1100, Los Angeles, California 90067 at 310-914-5007, by email to [email protected], or visit our website at www.frankcruzlaw.com.   If you inquire by email please include your mailing address, telephone number, and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

The Law Offices of Frank R. Cruz, Los Angeles
Frank R. Cruz, 310-914-5007
[email protected]
www.frankcruzlaw.com



LOOMING DEADLINE: Zhang Investor Law Reminds Investors with Losses of the Deadline in Securities Class Action Lawsuit Against Raytheon Technologies Corporation– RTX

NEW YORK, Dec. 18, 2020 (GLOBE NEWSWIRE) — Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Raytheon Technologies Corporation f/k/a Raytheon Company (NYSE: RTX, RTN) between February 10, 2016 and October 27, 2020, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 29, 2020.

To join the class action, go to http://zhanginvestorlaw.com/join-action-form/?slug=raytheon-technologies-corporation&id=2507 or call Sophie Zhang, Esq. toll-free at 800-991-3756 or email [email protected] for information on the class action.

如果您想加入这个集体诉讼案,请在这里提交您的信息。http://zhanginvestorlaw.com/join-action-form/?slug=raytheon-technologies-corporation&id=2507

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: Raytheon had inadequate disclosure controls and procedures and internal control over financial reporting; Raytheon had faulty financial accounting; as a result, Raytheon misreported its costs regarding Raytheon’s Missiles & Defense business since 2009; as a result of the foregoing, Raytheon was at risk of increased scrutiny from the government; as a result of the foregoing, Raytheon would face a criminal investigation by the U.S. Department of Justice; and as a result, Defendants’ public statements were materially false and/or misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

Lead plaintiff status is not required to seek compensation.  You may retain counsel of your choice.  You may remain an absent class member and take no action at this time.

Zhang Investor Law represents investors worldwide. Attorney Advertising. Prior results do not guarantee similar outcomes.

Zhang Investor Law P.C.
99 Wall Street, Suite 232
New York, New York 10005
[email protected]
tel: (800) 991-3756